Susan R. Rheingold, MD
The September 2017 FDA approval of tisagenlecleucel (Kymriah), the chimeric antigen receptor (CAR) T-cell therapy, has already made a significant impact on pediatric patients with acute lymphoblastic leukemia (ALL).
, Rheingold, medical director of the Oncology Outpatient Clinic, physician with the Cancer Center at Children’s Hospital of Philadelphia, discusses the impact of CAR T-cell therapy on patients with ALL and options for patients who relapse on treatment.
OncLive: What is the role of CAR T-cell therapy in pediatric ALL?
CAR T-cell therapy is not yet approved for upfront treatment. However, for relapsed disease, it has made a significant change in the number of children it will put back into remission and ultimately cure. It is probably the most promising new cancer therapy in a long time for any type of cancer. However, it is not a frontline therapy for newly diagnosed children; therefore, it will not be replacing frontline chemotherapy just yet.
Are there any other regimens in the pipeline that are showing a similar impact?
It is better to have relapsed ALL now rather than 10 years ago, because there is a whole class of immunotherapy drugs that are altering the treatment paradigm.
... to read the full story